XML 52 R41.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue - Additional Information (Details)
3 Months Ended 6 Months Ended
Jul. 04, 2021
USD ($)
Sep. 27, 2020
USD ($)
Agreement
Award
Jun. 28, 2020
USD ($)
Jul. 04, 2021
USD ($)
Jun. 28, 2020
USD ($)
Apr. 16, 2021
USD ($)
Jan. 03, 2021
USD ($)
Disaggregation Of Revenue [Line Items]              
Minimum reagent purchases over lease term       5 years      
Contract asset $ 47,300,000     $ 47,300,000     $ 42,800,000
Credit losses related to contract assets 0   $ 0 0 $ 0    
Deferred revenue, current 36,600,000     36,600,000     35,500,000
Deferred revenue, revenue recognized       26,800,000      
Revenue recognized 5,500,000   $ 4,000,000.0 12,600,000 $ 7,700,000    
Other Assets              
Disaggregation Of Revenue [Line Items]              
Contract asset 2,400,000     2,400,000     2,400,000
Other Liabilities              
Disaggregation Of Revenue [Line Items]              
Deferred revenue, non-current 6,000,000.0     6,000,000.0     6,600,000
Customer Supply Agreement              
Disaggregation Of Revenue [Line Items]              
Contract asset 14,300,000     14,300,000     15,100,000
Customer Supply Agreement | Other Assets              
Disaggregation Of Revenue [Line Items]              
Contract asset 2,400,000     2,400,000     2,400,000
Contractual Arrangements              
Disaggregation Of Revenue [Line Items]              
Contract asset 32,800,000     32,800,000     24,300,000
Contract Manufacturing Agreements              
Disaggregation Of Revenue [Line Items]              
Contract asset 200,000     200,000     $ 3,400,000
Biomedical Advanced Research and Development Authority              
Disaggregation Of Revenue [Line Items]              
Number of collaboration and license agreements | Agreement   2          
Number of awards under collaboration and license agreements | Award   2          
Biomedical Advanced Research and Development Authority | Maximum              
Disaggregation Of Revenue [Line Items]              
Potential payment receivable for development and submission of emergency use authorizations and 510(k) applications of COVID-19 tests   $ 13,600,000          
Additional awards granted, potential payment receivable for development and submission of emergency use authorizations and 510(k) applications of COVID-19 tests           $ 3,600,000  
Biomedical Advanced Research and Development Authority | Grant Revenue              
Disaggregation Of Revenue [Line Items]              
Revenue recognized $ 1,800,000     $ 5,800,000